NCT04996732

Brief Summary

Real-world studies on long-term prognosis in patients who underwent anti-tumor treatments during hospitalization from a hospital-based cancer registry in china.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
500,000

participants targeted

Target at P75+ for all trials

Timeline
191mo left

Started Jan 2008

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress54%
Jan 2008Dec 2041

Study Start

First participant enrolled

January 1, 2008

Completed
13.6 years until next milestone

First Submitted

Initial submission to the registry

August 2, 2021

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 9, 2021

Completed
19.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2040

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2041

Last Updated

August 9, 2021

Status Verified

August 1, 2021

Enrollment Period

33 years

First QC Date

August 2, 2021

Last Update Submit

August 2, 2021

Conditions

NeoplasmsSurvivalSurgeryRadiotherapyDrug Therapy

Keywords

CancerSurvivorship

Outcome Measures

Primary Outcomes (1)

  • Overall survival

    Death from any cause

    15 years

Secondary Outcomes (1)

  • Disease-free survival

    15 years

Study Arms (1)

All Cancers

subgroups according to cancer sites

Procedure: hospitalization

Interventions

hospitalizationPROCEDURE

Including various treatments such as surgery, radiotherapy, chemotherapy and immunotherapy during hospitalization

All Cancers

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All patients who completed tumor treatment (including surgery, radiotherapy, chemotherapy, immunotherapy, etc.) due to malignant tumors based on preoperative or intraoperative evaluation in Fudan University Shanghai Cancer Center during the study period.

You may qualify if:

  • All patients who completed tumor treatment (including surgery, radiotherapy, chemotherapy, immunotherapy, etc.) due to malignant tumors based on preoperative or intraoperative evaluation in Fudan University Shanghai Cancer Center during the study period.

You may not qualify if:

  • Patients who have not been treated during hospitalization;
  • Patients with non-malignant tumors.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fudan University Shanghai Cancer Center

Shanghai, China

RECRUITING

MeSH Terms

Conditions

Neoplasms

Interventions

Hospitalization

Intervention Hierarchy (Ancestors)

Patient CareTherapeuticsHealth ServicesHealth Care Facilities Workforce and Services

Central Study Contacts

Ying Zheng, Dr.

CONTACT

+8618121299522zhengying@fudan.edu.cn

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director of Cancer Prevention Department, Fudan University Shanghai Cancer Center

Study Record Dates

First Submitted

August 2, 2021

First Posted

August 9, 2021

Study Start

January 1, 2008

Primary Completion (Estimated)

December 31, 2040

Study Completion (Estimated)

December 31, 2041

Last Updated

August 9, 2021

Record last verified: 2021-08

Locations

CN(1)